Abeona Therapeutics crossed a threshold this year that most biotechs never reach: it turned sixteen years of gene-therapy research into an approved, commercially administered product. The FDA cleared ZEVASKYN in April 2025 as the first and only autologous cell-based gene therapy for the wounds of recessive dystrophic epidermolysis bullosa (RDEB), the first commercial patient was treated in December, and the fiscal first quarter was the first quarter in company history with a genuine product-sales line. That makes Q1 FY2026 a milestone quarter - and a small one. ZEVASKYN generated $8.7 million of net product revenue, a real number against a $20 million quarterly operating-cash burn and a $168 million cash pile, and the stock now trades at its 52-week high on a market value of roughly $420 million.
The central tension is a young launch priced for an adult one. The market is valuing Abeona not on its trailing quarter but on how fast ZEVASKYN penetrates a U.S. addressable population of roughly 750 moderate-to-severe RDEB patients whose wounds can be treated with a single surgical application of the therapy. One good quarter of gross sales does not prove that ramp; what would is a sustained, rising series of treatment-center activations and reorders. The balance sheet funds the wait - roughly two years at current burn, plus a $75 million ATM facility still about $51 million unused - so the question is execution, not survival. Against the one pure EB gene-therapy peer that made the same transition, Krystal Biotech, Abeona trades at a fraction of the market value on a fraction of the revenue; that comparison frames the upside and the proving ground in one.
The thesis, in one sentence: Abeona has cleared the hardest gate in biotech - FDA approval and first revenue - and the next twelve months decide whether ZEVASKYN becomes a compounding rare-disease franchise or a slow launch that the market's current enthusiasm overpays. The $7.40 share price already embeds a good deal of optimism; the reports that follow will put a price on the reality.